| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/21/2002 | US20020023277 Vascular endothelial zinc finger 1 gene and protein and uses thereof |
| 02/21/2002 | US20020022742 Salt forms of an HIV protease inhibitor |
| 02/21/2002 | US20020022720 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 02/21/2002 | US20020022716 Detecting modulator of protein activity; mix modulator and target protein complex, incubate with enzyme and substrate, measure enzyme activity, adjustment in activity indicates modulator |
| 02/21/2002 | US20020022715 Nervous system disorders; cardiovascular disorders; gastrointestinal disorders |
| 02/21/2002 | US20020022659 For therapy of viral infection |
| 02/21/2002 | US20020022658 Methods for selectively occluding blood supplies to neoplasias |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022623 A substituted hydroxyethylene compound useful for treating Alzheimer's disease, mild cognitive impairment, Down's syndrome, herediatary cerebral hemmorrhage with amyloidosis, degenerative dementia |
| 02/21/2002 | US20020022621 Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022599 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/21/2002 | US20020022596 Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them |
| 02/21/2002 | US20020022595 Treating inflammation resulting from a response of the non-specific defense system in a mammal by administering an antiinflammatory agent and the uncontaminated Mac-1 alpha subunit |
| 02/21/2002 | US20020022594 Overcoming Bcl-2 apoptosis resistance; administering a compound with calpain activity to cleave Bax to produce a Bax/p18 protein fragment |
| 02/21/2002 | US20020022593 Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
| 02/21/2002 | US20020022592 Delivery of thrombospondin from implantable tissue matrices |
| 02/21/2002 | US20020022591 Polynucleotides and polypeptides comprising an ovarian tumor protein, antibodies directed against said polypeptides; diagnostic kits |
| 02/21/2002 | US20020022590 Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms |
| 02/21/2002 | US20020022587 Administering a compound which increases a transient potassium (K+ ) current in the excitable cells of a patient; losartan, saralasin for example |
| 02/21/2002 | US20020022254 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | US20020022249 Nucleotide sequences which code enzymatic polypeptide; for use in the diagnosis and treatment of cancer and blood disorders |
| 02/21/2002 | US20020022248 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 02/21/2002 | US20020022060 Combined plant coagulate composition, process for the manufacture thereof and uses thereof |
| 02/21/2002 | US20020022053 Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis, and pharmaceutical compositions and kit related thereto |
| 02/21/2002 | US20020022051 For burns, injuries of skin; lyases enzyme on carrier |
| 02/21/2002 | US20020022035 Genetic engineering; deactivating toxin |
| 02/21/2002 | US20020022033 Diagnosis of Aids |
| 02/21/2002 | US20020022031 Immunotherapy for chronic myelocytic leukemia |
| 02/21/2002 | US20020022030 Product and process for regulation of T cell responses |
| 02/21/2002 | US20020022029 Human RRP sequences and methods of use |
| 02/21/2002 | US20020022028 Integrin antagonist; bone disorders |
| 02/21/2002 | US20020022027 Complexing to polypeptides; antiproliferation agent |
| 02/21/2002 | US20020022025 Anticoagulants |
| 02/21/2002 | US20020022024 Hemoglobinase inhibitors and methods of use |
| 02/21/2002 | US20020022023 Treatment of diabetes mellitus and insulin receptor signal transduction |
| 02/21/2002 | US20020022021 Method of regulating transcription in a cell |
| 02/21/2002 | US20020022015 Administration system for seronegative of hepatitis C virus |
| 02/21/2002 | US20020022005 Compositions for treating cystic fibrosis |
| 02/21/2002 | US20020022003 Method and composition for the treatment of cancer by the enzymantic conversion of soluble radioactive toxic precipitates in the cancer |
| 02/21/2002 | DE10025379A1 Bestimmung von NAALADase-Inhibitoren Determination of NAALADase inhibitors |
| 02/21/2002 | CA2804958A1 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | CA2457131A1 Oligonucleotides and other modulators of the nk-1 receptor pathway and therapeutic uses thereof |
| 02/21/2002 | CA2423592A1 Methods and compositions for the repair and/or regeneration of damaged myocardium |
| 02/21/2002 | CA2420032A1 Oral delivery of peptide |
| 02/21/2002 | CA2419855A1 Stimulating neutrophil function to treat inflammatory bowel disease |
| 02/21/2002 | CA2419790A1 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | CA2419725A1 Genes involved in immune related responses observed with asthma |
| 02/21/2002 | CA2419545A1 .alpha.7 nicotinic receptor peptides as ligands for .beta. amyloid peptides |
| 02/21/2002 | CA2419529A1 Diagnosis and treatment of tumor-suppressor associated disorders |
| 02/21/2002 | CA2419491A1 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | CA2419469A1 Derivatives of peptides and peptide mimetics having integrin inhibitor properties ii |
| 02/21/2002 | CA2419418A1 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | CA2419338A1 A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| 02/21/2002 | CA2419259A1 Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof |
| 02/21/2002 | CA2419245A1 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | CA2419133A1 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | CA2419033A1 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | CA2418988A1 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 02/21/2002 | CA2418725A1 Claudin polypeptides |
| 02/21/2002 | CA2418716A1 Integrin binding motif containing peptides and methods of treating skeletal diseases |
| 02/21/2002 | CA2418531A1 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | CA2418303A1 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | CA2417152A1 Therapeutic compounds for ovarian cancer |
| 02/21/2002 | CA2417141A1 Novel glycoproteins and methods of use thereof |
| 02/21/2002 | CA2417129A1 Obesity controlling method |
| 02/21/2002 | CA2416898A1 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | CA2416794A1 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | CA2387002A1 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/20/2002 | EP1180686A1 Remedies for kidney diseases and method for screening the same |
| 02/20/2002 | EP1180525A1 Transcriptional activation inhibitory protein |
| 02/20/2002 | EP1180524A1 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides |
| 02/20/2002 | EP1180371A1 Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin |
| 02/20/2002 | EP1180368A1 Freeze dried hgf preparations |
| 02/20/2002 | EP1180365A2 Aerosol formulations of peptides and proteins |
| 02/20/2002 | EP1180243A2 Uses of notch related genes |
| 02/20/2002 | EP1180239A2 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 02/20/2002 | EP1180164A2 Methods using of fab i and compounds modulating fab i activity |
| 02/20/2002 | EP1180156A1 Methods for induction of tolerance to adenoviral vectors and transgene products |
| 02/20/2002 | EP1180152A1 Recombinant bacterial phytases and uses thereof |
| 02/20/2002 | EP1180151A2 Protein kinases |
| 02/20/2002 | EP1180148A1 A VARIANT OF C6 BETA-CHEMOKINE LEUKOTACTIN-1(shLkn-1) WITH ENHANCED BIOLOGICAL ACTIVITY |
| 02/20/2002 | EP1180145A1 Biosynthesis of foreign proteins using transformed microalgae |
| 02/20/2002 | EP1180144A2 Cytoskeleton-associated proteins |
| 02/20/2002 | EP1180143A2 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 02/20/2002 | EP1180141A2 The p2x 3 receptor, methods of altering p2x 3receptor activity and uses thereof |
| 02/20/2002 | EP1180140A1 Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway |
| 02/20/2002 | EP1180123A1 Immunoconjugates having high binding affinity |
| 02/20/2002 | EP1180121A1 Long lasting insulinotropic peptides |
| 02/20/2002 | EP1180120A2 Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant |
| 02/20/2002 | EP1180118A1 Fimbrial proteins |
| 02/20/2002 | EP1180116A2 Fap-activated anti-tumor compounds |
| 02/20/2002 | EP1180114A1 Compositions, methods, and kits relating to resistin |
| 02/20/2002 | EP1180109A1 Prodrug activation using catalytic antibodies |
| 02/20/2002 | EP1180099A1 New compounds |
| 02/20/2002 | EP1180098A1 New compounds |
| 02/20/2002 | EP1180042A1 Model membrane systems |
| 02/20/2002 | EP1180040A2 Methods for treating congestive heart failure |
| 02/20/2002 | EP1180039A2 Factor for regulation of neurite growth |
| 02/20/2002 | EP1180038A2 Antifungal combination use |